دورية أكاديمية
Mitigating Radiotoxicity in the Central Nervous System: Role of Proton Therapy.
| العنوان: | Mitigating Radiotoxicity in the Central Nervous System: Role of Proton Therapy. |
|---|---|
| المؤلفون: | Winter SF; Department of Neurology and MGH Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. sfwinter@mgh.harvard.edu.; Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117, Berlin, Germany. sfwinter@mgh.harvard.edu.; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Junior Clinician Scientist Program, 10117, Berlin, Germany. sfwinter@mgh.harvard.edu., Vaios EJ; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA., Shih HA; Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Grassberger C; Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Parsons MW; Department of Psychiatry, Psychology Assessment Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Gardner MM; Department of Psychiatry, Psychology Assessment Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Ehret F; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Junior Clinician Scientist Program, 10117, Berlin, Germany.; Department of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 13353, Berlin, Germany.; Charité - Universitätsmedizin Berlin, Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany., Kaul D; Department of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 13353, Berlin, Germany.; Charité - Universitätsmedizin Berlin, Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany., Boehmerle W; Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117, Berlin, Germany., Endres M; Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117, Berlin, Germany.; Center for Stroke Research Berlin, Berlin, Germany.; ExcellenceCluster NeuroCure, Berlin, Germany.; German Center for Neurodegenerative Diseases (DZNE), partner site Berlin, Berlin, Germany.; German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany., Dietrich J; Department of Neurology and MGH Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. |
| المصدر: | Current treatment options in oncology [Curr Treat Options Oncol] 2023 Nov; Vol. 24 (11), pp. 1524-1549. Date of Electronic Publication: 2023 Sep 20. |
| نوع المنشور: | Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Current Science, Inc Country of Publication: United States NLM ID: 100900946 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-6277 (Electronic) Linking ISSN: 15346277 NLM ISO Abbreviation: Curr Treat Options Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, PA : Current Science, Inc., |
| مواضيع طبية MeSH: | Proton Therapy*/adverse effects , Central Nervous System Neoplasms*/radiotherapy, Child ; Adult ; Humans ; Protons ; Photons/therapeutic use ; Central Nervous System ; Radiotherapy Dosage |
| مستخلص: | Opinion Statement: Central nervous system (CNS) radiotoxicity remains a challenge in neuro-oncology. Dose distribution advantages of protons over photons have prompted increased use of brain-directed proton therapy. While well-recognized among pediatric populations, the benefit of proton therapy among adults with CNS malignancies remains controversial. We herein discuss the role of protons in mitigating late CNS radiotoxicities in adult patients. Despite limited clinical trials, evidence suggests toxicity profile advantages of protons over conventional radiotherapy, including retention of neurocognitive function and brain volume. Modelling studies predict superior dose conformality of protons versus state-of-the-art photon techniques reduces late radiogenic vasculopathies, endocrinopathies, and malignancies. Conversely, potentially higher brain tissue necrosis rates following proton therapy highlight a need to resolve uncertainties surrounding the impact of variable biological effectiveness of protons on dose distribution. Clinical trials comparing best photon and particle-based therapy are underway to establish whether protons substantially improve long-term treatment-related outcomes in adults with CNS malignancies. (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
| معلومات مُعتمدة: | R38 CA245204 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: Adult patients; Complications; Neurotoxicity; Protons; Radiation injury; Radiotoxicity |
| المشرفين على المادة: | 0 (Protons) |
| تواريخ الأحداث: | Date Created: 20230920 Date Completed: 20231114 Latest Revision: 20240605 |
| رمز التحديث: | 20240605 |
| DOI: | 10.1007/s11864-023-01131-x |
| PMID: | 37728819 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1534-6277 |
|---|---|
| DOI: | 10.1007/s11864-023-01131-x |